Bioavailability of controlled release mesalazine (5-ASA) preparations

Area of Science:

• Gastroenterology and Pharmaceutical Sciences

Background:

• Salazosulfapyridine, synthesized in 1941, was later found to have mesalazine (5-ASA) as its active therapeutic agent.
• The development of mesalazine (5-ASA) led to alternatives like olsalazine and pure mesalazine formulations (Asacol, Claversal, Pentasa).

Purpose of the Study:

• To compare the similarities and differences among various pure mesalazine controlled-release drugs.
• To investigate the impact of pharmaceutical design and physiological variations on drug efficacy.

Main Methods:

• Review of existing literature on salazosulfapyridine and its mesalazine-based successors.
• Analysis of pharmaceutical designs for controlled-release mesalazine formulations.
• Consideration of physiological factors: gastrointestinal pH, gastric emptying, and intestinal transit.

Main Results:

• While sharing similarities, pure mesalazine drugs exhibit significant differences in their controlled-release mechanisms.
• Variations in gastrointestinal pH, gastric emptying, and intestinal transit influence drug performance.
• Pharmaceutical design is a key factor, but physiological variability also plays a crucial role.

Conclusions:

• Pure mesalazine drugs, despite therapeutic similarities, possess distinct pharmaceutical characteristics.
• Understanding the interplay between drug formulation and patient-specific physiological variations is essential for optimizing mesalazine therapy.